Home » Newsletters » The Carlat Addiction Treatment Report

The Carlat Addiction Treatment Report

Opioid Use Disorder Treatment (July/August) | 2020

View Archived Issues

CME Post-Test - Opioid Use Disorder Treatment, CATR, July/August 2020

August 6, 2020

The post-test for this issue is available for one year after the publication date to subscribers only. By successfully completing the test you will be awarded a certificate for 1 CME credit. Read More

Note From the Editor-in-Chief

August 6, 2020

Benjamin Oldfield, MD

It’s become clear that the COVID-19 pandemic will obligate us to rebuild our practices anew—in some cases, permanently—and that achieving normalcy will be less like a return and more like a transformation. My hope is that this issue helps you construct that new normal. We examine specific telemedicine strategies for... Read More

“What About the Implant, Doc?” Appraising Various Formulations of Buprenorphine

August 6, 2020

Edmund S. Higgins, MD.

Buprenorphine can be administered via intravenous, transdermal, sublingual, buccal, and implanted formulations. We appraise the evidence for various formulations and suggest certain populations for which certain formulations may be a better choice. Read More

Telemedicine for Addiction Treatment: Evidence and Implementation Strategies

August 6, 2020

Dallas Swendeman, PhD, MPH

As many clinicians embark on new telemedicine efforts, we review the body of literature around virtual approaches to the care of patients with addiction. Dr. Swendeman reviews the evidence of efficacy for electronic self-monitoring, text-messaging, and other strategies may support your practice, and how to implement them. Read More

Updated Guidelines for Treating Opioid Use Disorder

August 6, 2020

Rehan Aziz, MD.

The American Society of Addiction Medicine released updated guidelines for the management of opioid use disorder (OUD) in March, 2020. They focus on expanding access to methadone and buprenorphine. Additionally, detailed guidance is given for perioperative management of OUD and pain management in patients with OUD. Read More

A Possible Option in Opioid-Related Harm Reduction

August 6, 2020

Greg Sazima, MD

Medications are the mainstay of treatment for opioid use disorder (OUD), but what if patients decline buprenorphine, injectable naltrexone, and methadone? In this randomized trial, authors compared hydromorphone (Dilaudid) with diacetylmorphine (the active ingredient in heroin) among patients who reported injecting heroin. Read More

Efficacy and Acceptability of Varenicline for Alcohol Use Disorder

August 6, 2020

Richard Moldawsky, MD

Smoking tobacco and drinking alcohol have reciprocal influences on each other. In this meta-analysis of nine randomized studies, the authors appraise the evidence for varenicline use for alcohol use disorder specifically. Read More